| abstract |
Kind Code: A1 One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of metabolic disorders in canines. Metabolic disorders include, for example, ketoacidosis, prediabetes, insulin-dependent diabetes, insulin-resistant diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia-induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia Dyslipidemia, subclinical inflammation, systemic inflammation, mild systemic inflammation, hepatic lipidosis, pancreatitis, metabolic disorders, such as hypertension, renal dysfunction and / or musculoskeletal disorders, and / or syndrome X Selected from the group consisting of: One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of canine metabolic disorders. [Selection diagram] None |